RT Journal Article
T1 Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
A1 Ocampo, A
A1 Domingo, P
A1 Fernandez, P
A1 Diz, J
A1 Barbera, J R
A1 Sepulveda, M A
A1 Salgado, X
A1 Rodriguez, M
A1 Santos, J
A1 Yzusqui, M
A1 Mayorga, M I
A1 Lorenzo, J F
A1 Bahamonde, A
A1 Bachiller, P
A1 Martinez, E
A1 Rozas, N
A1 Torres, C
A1 Muñoz, A
A1 Casado, A
A1 Podzamczer, D
K1 Adult
K1 Anti-HIV Agents
K1 Antiretroviral Therapy, Highly Active
K1 Drug Substitution
AB To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral regimens to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) in a real-world setting. PRO-STR is a 48 week prospective observational post-authorization study in 25 hospitals. Patients with a viral load  A total of 303 patients were included (mean age 46.6 years; male 74.0%; previous treatment 74.7% NNRTI and 25.3% PI/r). Both groups exhibited significantly reduced lipid profiles, except for HDL cholesterol, for which a non-significant increase was observed. [NNRTI patients: total cholesterol (baseline: 195.5 ± 38.4 mg/dL; week 48: 171.0 ± 35.5 mg/dL), total cholesterol/HDL ratio (baseline: 4.2 ± 1.2; week 48: 4.0 ± 1.2), HDL (baseline: 49.1 ± 12.0 mg/dL; week 48: 49.2 ± 45.8 mg/dL), LDL (baseline: 119.2 ± 30.2 mg/dL; week 48: 114.2 ± 110.7 mg/dL), and triglycerides (baseline: 136.6 ± 86.8 mg/dL; week 48: 113.4 ± 67.8 mg/dL); PI/r patients: total cholesterol (baseline: 203.2 ± 48.8 mg/dL; week 48: 173.4 ± 36.9 mg/dL), total cholesterol/HDL ratio (baseline: 4.7 ± 1.6; week 48: 4.0 ± 1.2), HDL (baseline: 46.4 ± 12.5 mg/dL; week 48: 52.1 ± 54.4 mg/dL), LDL (baseline: 127.0 ± 36.3 mg/dL; week 48: 111.4 ± 35.8 mg/dL), and triglycerides (baseline: 167.6 ± 107.7 mg/dL; week 48: 122.7 ± 72.1 mg/dL)]. The most common intolerances were neuropsychiatric in the NNRTI patients and gastrointestinal and metabolic in the PI/r patients, and these intolerances were significantly reduced in both groups at week 48 [NNRTI: neuropsychiatric (baseline: 81.3%; week 48: 0.0%); PI/r: gastrointestinal (baseline: 48.7%; week 48: 0.0%) and metabolic (baseline: 42.1%; week 48: 0.0%)]. RPV/FTC/TDF improved the lipid profiles and reduced the intolerances after switching from NNRTI or PI-based regimens, in a cohort of HIV-infected patients.
PB Oxford University Press
YR 2018
FD 2018-04-16
LK http://hdl.handle.net/10668/12495
UL http://hdl.handle.net/10668/12495
LA en
NO Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, Sepúlveda MA, et al. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. J Antimicrob Chemother. 2018 Aug 1;73(8):2171-2176
DS RISalud
RD Apr 19, 2025